Some suggestions from the Agency’s directors on the texts of the Resolutions to be deliberated on Tuesday (8/10) on cultivation and registration of cannabis-based medicines need to be evaluated. Tema returns to the agenda of Anvisa’s Board of Directors at the next meeting, scheduled for October 15th.

Voting on proposals for medicinal cannabis was postponed until 15 October.

Initially, topics discussing criteria for cultivation and registration of plant-based drugs would be deliberated at the Board meeting on Tuesday (10/08).

However, some suggestions from the Agency directors were presented to the text. Prior to consideration by the Board of the Agency, the new considerations will be evaluated by the technical areas related to the topic, as well as by the Anvisa Attorney.

See more at

Also see

Brazil postpones vote on key marijuana proposals, raising questions about their future